A study discovered current warming from methane and nitrous oxide in the Amazon Basin offsets-and most likely exceeds-the ability it has to soak up CO2.
Published: Mar 15, 2021
March 15, 2021 11:00 UTC
Sesen Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Significant Regulatory and Commercial Readiness Progress for
the Company’s Lead Product Candidate Vicineum™
Strengthened balance sheet: $98 million in cash and cash equivalents as of February 28, 2021
1
Marketing Authorization Application submitted in Europe with potential approval in early 2022
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full-year ended December 31, 2020. The Company’s lead program, Vicineum, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In February 2021, the Food and Drug Administration (FDA) accepted for filing the Company s Biologi
HPV vaccine may not be cost-effective in adult populations aged over 26 years eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Financial worries can hamper the success of cancer treatment and raise patients risk of death, according to a new study that offers the first evidence of such a link.
(1)
LAS VEGAS, March 4, 2021 /PRNewswire/ Rare cancers account for approximately 22% of all the diagnosed cancer cases. The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100?000 per year.
However, these cases are not confined to one or the other particular geography, but are disproportionately spread across the world. Many rare human cancers are not curable, and have limited number of treatment options. Rare cancers are more difficult to diagnose and are often misdiagnosed. Rarity of the cancers further complicates the running of clinical trials. Lack of clinical expertise, research, and funding are other barriers in the Rare cancer market.